Head to head
Setmelanotide against Semaglutide
An approved drug for rare genetic obesity against an approved drug for common obesity. They are not alternatives: setmelanotide works in people with specific defects in the melanocortin pathway, and the case for it rests on that population rather than on effect size.
Column A
SetmelanotideSetmelanotide (MC4R agonist)
An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Setmelanotide | Semaglutide |
|---|---|---|
| Category | Melanocortin | Metabolic |
| FDA status | FDA-approved (Imcivree) for specific genetic obesity indications | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~11 hours | ~7 days |
| Molecular weight | 1,117.3 Da | 4,113.6 Da |
| Mechanism | Selectively agonizes the melanocortin-4 receptor (MC4R) to restore satiety signaling disrupted by upstream genetic defects. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Setmelanotide and Semaglutide?
Setmelanotide: An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Setmelanotide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Setmelanotide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Setmelanotide and Semaglutide FDA-approved?
Setmelanotide: FDA-approved (Imcivree) for specific genetic obesity indications. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Setmelanotide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.